Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (PreCePRA)
Phase of Trial: Phase III
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms PreCePRA
- 17 Jun 2017 Interim analysis results (n=50) presented at the 18th Annual Congress of the European League Against Rheumatism
- 16 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
- 16 May 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2018.